Bavarian Nordic Deal Opens Up Potential China Market For RSV Vaccine
Company Lags Behind Big Players, But Could Seize Asian Opportunity
As three big players get set to reveal pivotal data for adult RSV vaccines, Bavarian Nordic seals a deal for its candidate that could still claim a sizeable niche if a late-stage trial delivers.
You may also be interested in...
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.
GSK’s drug is the first in the class to show non-inferiority to standard therapy in safety, but the data still contains areas of doubt.
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.